Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $32.39 million. The enterprise value is $2.86 million.
| Market Cap | 32.39M |
| Enterprise Value | 2.86M |
Important Dates
The next estimated earnings date is Thursday, May 16, 2024, before market open.
| Earnings Date | May 16, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 50.55 million shares outstanding.
| Shares Outstanding | 50.55M |
| Owned by Insiders (%) | 1.66% |
| Owned by Institutions (%) | 8.91% |
| Float | 46.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.74 |
| Forward PS | 1.87 |
| PB Ratio | 2.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.96, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.96 |
| Quick Ratio | 4.95 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -23.78 |
Financial Efficiency
Return on equity (ROE) is -142.70% and return on invested capital (ROIC) is -195.14%.
| Return on Equity (ROE) | -142.70% |
| Return on Assets (ROA) | -45.10% |
| Return on Capital (ROIC) | -195.14% |
| Revenue Per Employee | $39,718 |
| Profits Per Employee | -$168,162 |
| Employee Count | 142 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 5.27 |
Taxes
| Income Tax | -33,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3.39% in the last 52 weeks. The beta is 1.16, so Evogene's price volatility has been higher than the market average.
| Beta (1Y) | 1.16 |
| 52-Week Price Change | +3.39% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 31.76 |
| Average Volume (30 Days) | 167,448 |
Short Selling Information
| Short Interest | 86,448 |
| Short Previous Month | 71,606 |
| Short % of Shares Out | 0.17% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.55 |
Income Statement
In the last 12 months, Evogene had revenue of $5.64 million and -$23.88 million in losses. Loss per share was -$0.52.
| Revenue | 5.64M |
| Gross Profit | 3.95M |
| Operating Income | -26.51M |
| Pretax Income | -23.91M |
| Net Income | -23.88M |
| EBITDA | -20.34M |
| EBIT | -22.95M |
| Loss Per Share | -$0.52 |
Balance Sheet
The company has $31.06 million in cash and $1.53 million in debt, giving a net cash position of $29.53 million or $0.58 per share.
| Cash & Cash Equivalents | 31.06M |
| Total Debt | 1.53M |
| Net Cash | 29.53M |
| Net Cash Per Share | $0.58 |
| Equity / Book Value | 12.05M |
| Book Value Per Share | 0.24 |
| Working Capital | 27.53M |
Cash Flow
In the last 12 months, operating cash flow was -$21.58 million and capital expenditures -$759,000, giving a free cash flow of -$22.34 million.
| Operating Cash Flow | -21.58M |
| Capital Expenditures | -759,000 |
| Free Cash Flow | -22.34M |
| FCF Per Share | -$0.49 |
Margins
Gross margin is 70.00%, with operating and profit margins of -470.00% and -423.39%.
| Gross Margin | 70.00% |
| Operating Margin | -470.00% |
| Pretax Margin | -423.97% |
| Profit Margin | -423.39% |
| EBITDA Margin | -360.55% |
| EBIT Margin | -406.86% |
| FCF Margin | -396.03% |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.86% |
| Shareholder Yield | -10.86% |
| Earnings Yield | -73.72% |
| FCF Yield | -68.95% |
Analyst Forecast
The average price target for Evogene is $3.62, which is 464.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.62 |
| Price Target Difference | 464.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 19, 2013. It was a reverse split with a ratio of 1:2.
| Last Split Date | Nov 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
Evogene has an Altman Z-Score of -6.92 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.92 |
| Piotroski F-Score | 4 |